Preview_top5_resolutions

Feel free to borrow our Top 5 Resolutions. After these all of the rest are just small stuff.

WNMyeloma's Avatar
WNMyeloma shared a photo
Preview_happiness__peace__love__joy__health

We can all use more happiness, peace, love, joy, and good health. Pass it on to someone that needs it.

WNMyeloma's Avatar
WNMyeloma shared a photo
Preview_0

One of our own, Jim Bond, shared his American Cancer Society video with us. He is a 25+ year survivor of Multiple Myeloma. Listen to his video and get inspired.

WNMyeloma's Avatar
WNMyeloma shared a video
Preview_a_good_day_is_coming

We hope your day comes soon!

WNMyeloma's Avatar
WNMyeloma shared a photo
Preview_what_if_today_we_were_thankful_for_everything

Here's a thought!

WNMyeloma's Avatar
WNMyeloma shared a photo
Preview_fda_approved

The U.S. Food and Drug Administration (FDA) has approved — with conditions — Xpovio (selinexor) tablets, in combination with the corticosteroid dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma who received at least four prior therapies and failed to respond to treatment. The combo is designed for patients whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

The endorsement — called accelerated approval by the FDA — allows a medication addressing an unmet need in a serious condition to be used if it shows benefit on surrogate or interim measures made in a clinical trial. But its continued use, and full approval, requires a further showing of efficacy in a confirmatory study.

Xpovio, Karyopharm Therapeutics‘ lead compound, is a first-in-class oral inhibitor of the XPO1 protein that prevents tumor suppressor proteins from exiting the cell nucleus. This leads to cancer cell death while leaving healthy cells unharmed.

After designating Xpovio an orphan drug, the FDA granted it fast track status, and now has given the therapy accelerated approval.

“Today we approved a treatment under our accelerated approval program that provides a treatment option for patients with multiple myeloma with no available therapy,” Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence, said in a press release.

“While there is no cure for multiple myeloma, there are FDA-approved treatments to target the cancer and slow down the spread of the disease. Sadly, often over time, patients can exhaust all available treatments and still see their disease progress,” said Pazdur, the acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research (CDER).

“With today’s accelerated approval of Xpovio by the FDA, patients with heavily pretreated multiple myeloma will now have a new therapeutic option to treat their disease,” Sharon Shacham, PhD, MBA, founder, president, and chief scientific officer of Karyopharm, said in a company-issued press release.

“Discovering, developing and securing FDA approval for Xpovio with its novel mechanism of action over the past decade required the dedication of many people, including the patients, caregivers and physicians involved in our clinical trials, along with the many employees at Karyopharm. We are tremendously grateful for everyone’s contributions to this important milestone, and we look forward to the next stage in our pursuit of improving the lives of patients with cancer,” Shacham added.

The FDA’s accelerated approval was based on findings from the multicenter, single-arm, open-label, STORM Phase 2b trial (NCT02336815).

The study assessed the safety and efficacy of Xpovio (80mg), in combination with dexamethasone (20mg), in relapsed or refractory multiple myeloma patients who had received at least three prior therapies. The treatment was given twice per week until disease progression, death, or unacceptable toxicity.

In Part 2 of STORM, treatment efficacy and safety were assessed in a group of 83 people who failed to respond to therapy with two proteasome inhibitors, Velcade (bortezomib) and Kyprolis (carfilzomib), two immunomodulatory agents, Revlimid (lenalidomide) and Pomalyst (pomalidomide), and the anti-CD38 monoclonal antibody Darzalex (daratumumab).

Study findings showed that 25.3% of patients responded to the Xpovio-dexamethasone combination, with a median duration of response of 3.8 months and a median time to first response of 4 weeks.

The most common side effects of treatment reported in the 202 patients who participated in Part 1 and 2 of STORM were low platelet count (thrombocytopenia), low white blood cell count (neutropenia), and low red blood cell counts (anemia). Other common side effects included fatigue, nausea, vomiting, diarrhea, decreased appetite, weight loss, constipation, upper respiratory tract infections, and low blood sodium levels (hyponatremia).

Treatment was discontinued due to side effects in 27% of the participants. More than half of the patients (53%) required a reduction in the dose of Xpovio during the trial, and 65.3% had to interrupt treatment with Xpovio. Fatal adverse reactions were reported in 8.9% of patients.

Xpovio’s effectiveness, in combination with Velcade and low-dose dexamethasone, will be confirmed in the ongoing, randomized, BOSTON Phase 3 trial (NCT03110562). If proven effective, Xpovio will receive FDA’s full approval to be used together with dexamethasone as a therapy for heavily treated patients.

According to Karyopharm, Xpovio should become available to patients living in the U.S. no later than July 10, 2019. The full prescribing information, including dosing, scheduling and side effects, can be found here.

The company, meanwhile, is waiting for feedback from the European Medicines Agency (EMA) regarding its marketing authorization application (MAA). That MAA seeks the approval of Xpovio for the same indication in the E.U.

WNMyeloma's Avatar
WNMyeloma shared a photo
Preview_the_worst_thing_about_cancer_is_the_new_me

So true, has anyone else had this trouble?

WNMyeloma's Avatar
WNMyeloma shared a photo
Preview_stop_being_angry

Too many people are being too angry. That usually doesn't accomplish much. Let it flow, work around it, or work through it.

WNMyeloma's Avatar
WNMyeloma shared a photo
Preview_all_things_are_broken

Are you trying to put your broken pieces back together? Let your light shine, and you will come together.

WNMyeloma's Avatar
WNMyeloma shared a photo
Preview_hard_times_whip_superman

How many of you have felt this way? Maybe Superman should bring Batman for backup?

WNMyeloma's Avatar
WNMyeloma shared a photo
Preview_multiple_myeloma_hope_is_all_we_have

Keep Hope Alive MM fighters!

WNMyeloma's Avatar
WNMyeloma shared a photo
Preview_mm_blood_test

Chip-based cancer test may replace painful bone biopsy
The blood test, described in the journal Integrative Biology, uses a small plastic chip about the size of a credit card

Scientists have developed a low-cost, reliable blood test for multiple myeloma that uses a small plastic chip about the size of a credit card, which could make painful bone biopsies a relic of the past.

The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy, said researchers from University of Kansas in the US.

During that procedure, doctors insert a bone-biopsy needle through an incision to get a bone marrow sample - or make a larger incision and remove a section of bone via surgery.

Read Full Article>>http://www.business-standard.com/article/current-affairs/chip-based-cancer-test-may-replace-painful-bone-biopsy-118042000553_1.html

WNMyeloma's Avatar
WNMyeloma shared a photo